NeurogesX, Inc. (NASDAQ: NGSX) is seeing shares plunge after the Food & Drug Administration issued a complete response letter denying approval for the company’s Qutenza patch to assist with HIV-related pain symptoms. Fierce Biotech noted, “As expected, the FDA has rejected NeurogesX’s application to expand the use of Qutenza, which clearly came as no surprise to management.”
Unfortunately, the company is letting go of more than half its staff. The company will now focus on another program and on maintaining and raising capital.
The latest move indicates that 43 workers will be fired and 32 workers will be left to set up a late-stage study of NGX-1998 in postherpetic neuralgia. The company will not be investing further into Qutenza.
What we want to know is whether or not the company can even attract new capital based upon NGX-1998 or other prospects.
A 19% drop was down to $0.532 today and the 52-week trading range is $0.50 to $4.47. The market cap is a mere $15.8 million.
R&D expenses were $2.4 million in the fourth quarter and selling, general and administrative expenses for the fourth quarter of 2011 were $7.5 million. Cash, cash equivalents and short-term investments were $34.3 million at December 31, 2011, but the company did complete a $3 million private placement since the end of the year. If you tally up all of the assets and liabilities, NeurogesX has more liabilities than it does assets.
It is fair to ask… Can this company survive?
JON C. OGG
Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.